Vital Signs - MicroRNA... From Practice Squad Reject to MVP


USD 1,500

* Required Fields

USD 1,500


Be the first to review this product

This issue of Vital Signs, released on June 2, 2008, provides an strategic overview of issues surrounding the growth of microRNA research and use in drug discovery. Additionally, a company spotlight is provided for Miragen Therapeutics, Inc., a biopharmaceutical company seeking to develop medicines based on regulating microRNA. Reimbursement and regulatory news from the FDA is also provided for the week of May 19 - May 23, 2008.

Table of Contents

Vital Signs - MicroRNA... From Practice Squad Reject to MVPVital Signs: 2 June 2008This week's issue:

Related Research

Release Date : 26-Sep-17

Region : North America

Release Date : 25-Sep-17

Region : North America

Release Date : 19-Sep-17

Region : North America

Release Date : 08-Sep-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.